The global biologics contract development and manufacturing organization (CDMO) market was valued at USD 12.54 billion in 2022. It is estimated to reach USD 32.89 billion by 2031, growing at a CAGR of 11.31% during the forecast period (2023–2031). The global CDMO market penetration rate is increasing steadily, driven by increasing drug development and manufacturing outsourcing by pharma and biotech companies and ongoing divestment of non-core manufacturing facilities, adding capacity and new outsourced products to the sector.
Market Scope and Research Methodology
This report includes a multi-level regional assessment spanning global, regional, and country-specific markets. The analysis highlights market penetration, regional market leadership, and the strategic approaches adopted by prominent companies. A detailed SWOT analysis identifies the strengths, weaknesses, opportunities, and challenges within the market.
The primary goal of the Biologics Contract Development and Manufacturing Organization (CDMO) Market Report is to provide clear insights into market behavior, emerging trends, and the factors influencing market performance. The study evaluates market structure, segmentation, and forecasted market size while examining growth drivers, industry barriers, and opportunities stemming from technological progress, regulatory frameworks, cost efficiencies, and evolving consumer needs.
Download Exclusive Research Report PDF Sample: (Including Full TOC, List of Tables & Figures, Chart): https://straitsresearch.com/report/biologics-contract-development-and-manufacturing-organization-cdmo-market/request-sample
Regional Insights
The report presents an in-depth regional assessment of the Biologics Contract Development and Manufacturing Organization (CDMO) Market across North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Each region is analyzed based on key parameters such as market size, growth rate, trade activities, and overall industry development. This segmentation supports a deeper understanding of the competitive dynamics and market potential within each geographical area.
Market Segmentation
- By Type
- Mammalian
- Non-mammalian (Microbial)
- By Product Type
- Biologics
- Biosimilars
Key Market Players
- Catalent
- Boehringer Ingelheim Group
- JRS Pharma
- Toyobo Co. Ltd
- Parexel International Corp.
- Binex Co. Ltd
- JRS Pharma
- Lonza Group
- Fujifilm Diosynth Biotechnologies USA Inc.
- Samsung Biologics
Download Exclusive Research Report PDF Sample: (Including Full TOC, List of Tables & Figures, Chart): https://straitsresearch.com/report/biologics-contract-development-and-manufacturing-organization-cdmo-market/request-sample
Key Questions Addressed
- What is Biologics Contract Development and Manufacturing Organization (CDMO) Market?
- What was the market size of the Biologics Contract Development and Manufacturing Organization (CDMO) Market in 2024?
- What CAGR is expected for the market during the forecast period?
- Which factors are expected to drive market growth?
- What are the major segments of the market?
- Which strategies are companies adopting to strengthen their market presence?
- What emerging applications and trends are shaping the industry?
- Who are the key players in the Biologics Contract Development and Manufacturing Organization (CDMO) Market?
- What are the portfolios and competencies of leading market participants?
About Us
For over a decade, Straits Research has been a trusted partner to more than 2,590 small and large enterprises, empowering senior leaders and decision-makers with actionable intelligence to navigate complex markets. Our structured syndicate reports, published year-round, cover critical sectors such as chemicals, materials, food and beverage, healthcare, pharmaceuticals, automotive, technology, aerospace, and defense. Combined with our custom research tailored to client-specific needs, we deliver insights that drive business progress and informed decision-making.
